Download PDF
CC BY-NC-ND 4.0 · Neurology International Open 2018; 2(02): E118-E123
DOI: 10.1055/s-0044-100184
Review
Eigentümer und Copyright ©Georg Thieme Verlag KG 2018

Off-Label Use in Rare Diseases: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes

Rudolf Janzen
Further Information

Publication History

Publication Date:
18 April 2018 (online)

   Permissions and Reprints

Abstract

The off-label use of licensed drugs is widespread, and the risk of adverse events is elevated, especially if the scientific evidence is low. The treatment of rare diseases (<5/10,000) therefore may increase the risk of off-label use. The optimized standard treatment is primarily based on the regulatory decisions of the German Federal Joint Committee. The valid guidelines and the regulations of the German health system are discussed in this article. The criteria for indication and monitoring of off-label use are shown, especially focused on the problem of refractory myasthenia gravis. Escalation of treatment results regularly in off-label use. The arguments within the applicable guidelines should be followed. Some new aspects of the European regulations are likewise discussed.

Key words

off-label use - refractory myasthenia gravis - Lambert-Eaton myasthenic syndrome - congenital myasthenic syndrome
 

  • References

  • 1 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) www. bfarm.de
    PubMed
  • 2 Erhebung des Off-Label-Use ind der EU (2017) www.https://ec. europa.eu/…2017_2_28_finalstudy_report_on_off-label_use.pdf
    PubMed
  • 3 Janzen RWC, Ludwig WD. Off-Label-Therapie: aktuelle Probleme aus Sicht der Arzneimittelkommission der deutschen Ärzteschaft. Z Rheumatol 2012; 71: 108-118
    CrossrefPubMedGoogle Scholar
  • 4 Clemens T. Zulässigkeit von Arzneiverordnungen und Kostenregresse gegen Ärzte – Off-Label-Use und Unlicensed Use. GesR 7/2011 397-409
    PubMedGoogle Scholar
  • 5 Bundessozialgericht ( B 1 KR 1/16R) vom 13.12.2016
    PubMed
  • 6 Bundesverfassungsgericht (1 BvR 452/17) vom 11.4.2017
    PubMed
  • 7 Janzen RWC. Off-Label-Use im Behandlungsalltag. Arzneiverordnungen in der Praxis 43: 127-132
    PubMedGoogle Scholar
  • 8 European Federation of Neurological Associations (EFNA) board Declaration: Good Off-Label Use Practices (GOLUP) 2017 www. braincouncil.eu/activities/golup
    PubMed
  • 9 Orphanet ( www.orpha.net/national/DE-DE/index/startseite )
    PubMed
  • 10 Boldingh M, Maniaal AH. Bruborg et al. Geographical distribution of myasthenia gravis in Northern Europe–Results from a population-based study from two countries. Neuroepidemiology 2015; 44: 221-231
    CrossrefPubMedGoogle Scholar
  • 11 Breiner A, Widdifield J, Katzberg HD. et al. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Dis 2016; 26: 41-46
    CrossrefPubMedGoogle Scholar
  • 12 Müller-Oerlinghausen B, Schulz M. Abruptes Ende der systematischen Aufbereitung des Altarzneimittelmarkts im Bereich Psychiatrie, Neurologie und Anästhesie. Nervenarzt 1996; 67: 1040 - 1045
    CrossrefPubMedGoogle Scholar
  • 13 Gemeinsamer Bundesausschuss (G-BA) ( www.g-ba.de )
    PubMed
  • 14 Leitlinien der Deutschen Gesellschaft für Neurologie (DGN), 1.4.2017 ( www.dgn.org )
    PubMed
  • 15 Andersen JB, Owe JF, Engeland A. et al. Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study. Eur J Neurol 2014; 21: 948-955
    CrossrefPubMedGoogle Scholar
  • 16 Wöhrle G. Untersuchungen zu Epidemiologie und Verlauf der Myasthenia gravis in Deutschland. Dissertation, TU Darmstadt 2000
    PubMed
  • 17 Iorio R, Damato V, Albioni PE. et al. Efficacy and safety of rituximab for myasthenia gravis: a systematic reviews and meta-analysis. J Neurol 2015; 262: 1115-1119
    CrossrefPubMedGoogle Scholar
  • 18 Gilhus NE, Verschuur JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015; 14: 1023-1036
    CrossrefPubMedGoogle Scholar
  • 19 Dalakas MC. Novel future therapeutic options in myasthenia gravis. Autoimmun Rev 2013; 12: 936-941
    CrossrefPubMedGoogle Scholar
  • 20 Engel AG, Shen XM, Selcen D. et al. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 2015; 14: 420-434
    CrossrefPubMedGoogle Scholar
  • 21 Vrinten C, Lipka AF, van Zwet EW. et al. Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials. BMJ Open 2015; 5: e007863
    CrossrefPubMedGoogle Scholar
  • 22 Burns TM, Smith GA, Allen JA. et al. Editorial by concerned physicians: Unintended effect of the Orphan Drug Act on the potential cost of 3,4-diaminopyridine. Muscle Nerve 2016; 53: 165-168
    CrossrefPubMedGoogle Scholar
  • 23 Howard JF, Barohn RJ, Cutter GR. et al. A randomized, double-blind, placebo-controled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013; 48: 76-84
    CrossrefPubMedGoogle Scholar
  • 24 Howard Jr JF, Freimer M, O'brien F. et al. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis. Muscle Nerve. 2016; 56: 328-330
    PubMedGoogle Scholar
  • 25 www.ema.eu/docs/en_GB/document_library/summary_of_opinion/ 000791/WC500229915.pdf (30.07.2017)
    PubMed
  • 26 Bungard S, Rohn H, Döbler K. Zertifizierung von Myastheniezentren: Entwicklung und Implementierung eines Zertifizierungsprozesses für Selbsthilfeorganisationen. Z Evid Fortbild Qual Gesundhwes 2011; 105: 49-53
    CrossrefPubMedGoogle Scholar
  • 27 Pohanka M. Acetylcholinesterase inhibitors: a patent review (2008-present). Exp Opin Ther Pat 2012; 22: 871-886
    CrossrefPubMedGoogle Scholar
  • 28 Henze T, Janzen RWC, Schumm F. et al. Immuntherapie bei Myasthenia gravis und Lambert-Eaton-Syndrom. Teil 1: Medikamentöse Immunsuppression. Akt Neurologie 2010; 37: 505-517
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Urban P, Jacobi C, Jander S. Myasthenia gravis: Treatment standards and patient-tailored therapy. Akt Neurol 2018; 45: 253-262
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Silvestri NJ, Palace JA. Recognizing refractory myasthenia gravis. Fast Facts. Health Press Limited; Oxford: 2017
    PubMed
  • 31 Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory. myasthenia gravis patients. Yale J Biol Med 2013; 86: 255–260
    PubMed
  • 32 Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014; 175: 408-418
    CrossrefPubMedGoogle Scholar
  • 33 Alshekhlee A, Miles JD, Katirji B. et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009; 72: 1548 -1554
    CrossrefPubMedGoogle Scholar
  • 34 Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis 2014; 15: 167-178
    CrossrefPubMedGoogle Scholar
  • 35 Della Marina A, Tripp H, Lutz S. et al. Juvenile myasthenia gravis: recommendations for diagnostic approaches and treatment. Neuropediatrics 2014; 45: 75-83
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Wagner S, Janzen RWC, Mohs C. et al. Langzeitbehandlung der therapierefraktären Myasthenia gravis mittels Immunadsorption. Dtsch Med Wochenschr 2008; 133: 2377-2382
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Robeson KR, Kumar A, Keung B. et al. Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis. JAMA Neurol 2017; 74: 60-66
    CrossrefPubMedGoogle Scholar
  • 38 Tandan R, Hehir MK, Waheed W. et al. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 2017; 56: 185-196
    CrossrefPubMedGoogle Scholar
  • 39 Hoffmann S, Meisel A. Escalation strategies in the treatment of refractory myasthenia gravis. Akt Neurol 2018; 45: 294-297
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Rodríguez Cruz PM, Palace J, Ramjattan H. et al. Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes. Neurology 2015; 85: 1043-1047
    CrossrefPubMedGoogle Scholar
  • 41 Fernandes Oliveira E, Nacif AH. et al. Sleep disorders in patients with myasthenia gravis: a systematic review. J Phys Ther Sci 2015; 27: 2013-2018
    CrossrefPubMedGoogle Scholar
  • 42 Kohler S, Meisel A. The Lambert-Eaton myasthenic syndrome: An overview. Akt Neurol 2018; 45: 298-304
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Vrinten C, van der Zwaag AM, Weinreich SS. et al. Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes. Cochrane Database Syst Rev 2014; 12: CD010028
    PubMedGoogle Scholar
  • 44 Schara U, Della Marina A, Abicht A. Congential myasthenic syndromes: current diagnostic and therapeutic approaches. Neuropediatrics 2012; 43: 184-193
    Article in Thieme ConnectPubMedGoogle Scholar